Solasta Ventures
Home Approach Portfolio
News Team Hatchery Contact
HomeApproachPortfolio
Solasta Ventures
NewsTeamHatcheryContact
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
Nia JulianJune 28, 2021
Facebook0 Twitter Pinterest0 0 Likes
Previous

Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis

Nia JulianJune 30, 2021
Next

Xilio Therapeutics Announces FDA Acceptance of IND Application for XTX101 for the Treatment of Solid Tumors

Nia JulianJune 17, 2021

© 2020 Solasta Ventures. All Rights Reserved.